Abstract 1545P
Background
To evaluate the efficacy and safety of Endostar combined with concurrent chemoradiotherapy (CCRT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).
Methods
From May 2017 to February 2021, 92 patients with unresectable thoracic ESCC, clinical staged as IB to IVB disease based on the 8th edition of the American Joint Committee on Cancer (stage IVB: Only metastasis to supraclavicular/celiac lymph nodes) and local recurrence, were enrolled and randomly allocated in Endostar plus concurrent chemoradiotherapy (CCRT)(intervention group; n=46) and concurrent chemoradiotherapy (CCRT) (control group; n=48). Five or six cycles of Endostar (7.5mg/m2/24h ×120h, 7 days/cycle) were delivered in intervention group. The primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS), 1-year and 2-year overall survival rate and adverse events (AE).
Results
The median age was 63(interquartile range, 50-77) years in intervention group and 65(interquartile range, 52-79) years in control group. A total of 68 patients (74%) had stage III and IV disease. The intervention group had a significant higher complete response rate (ORR) than the control group (80% vs. 63.8%; P<0.05). The 1- and 2-year overall survival rates were 88.1% and 75.2% in intervention group, 87.4% and 62.3% in control group, respectively (P>0.05). The were no significant differences in the incidence of grade 3 or higher toxic effects between the intervention group and control group (P>0.05).
Conclusions
The median age was 63(interquartile range, 50-77) years in intervention group and 65(interquartile range, 52-79) years in control group. A total of 68 patients (74%) had stage III and IV disease. The intervention group had a significant higher complete response rate (ORR) than the control group (80% vs. 63.8%; P<0.05). The 1- and 2-year overall survival rates were 88.1% and 75.2% in intervention group, 87.4% and 62.3% in control group, respectively (P>0.05). The were no significant differences in the incidence of grade 3 or higher toxic effects between the intervention group and control group (P>0.05).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1532P - Phase Ib study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Updated results of antitumor activity and tolerability results in combination with chemotherapy
Presenter: Shun Yamamoto
Session: Poster session 21
1535P - Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the oesophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase II IKF-S627/RAMOS trial of the AIO
Presenter: Magdalena Scheck
Session: Poster session 21
1536P - HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+ advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome
Presenter: Joshua Tobias
Session: Poster session 21
1537P - A phase I study of pevonedistat plus capeOX in patients with advanced gastric cancer refractory to platinum (NCCH-1811)
Presenter: Daisuke Takahari
Session: Poster session 21
1540P - Tislelizumab combined with neoadjuvant chemoradiotherapy for resectable locally advanced oesophageal squamous cell carcinoma: A prospective, phase II clinical study
Presenter: Yi Zhang
Session: Poster session 21
1541P - Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC)
Presenter: Yinjun Dong
Session: Poster session 21